Macrovascular involvement in systemic sclerosis: Comorbidity or accelerated atherosclerosis? Jelena BlagojevicMarco Matucci Cerinic Invited Commentary 20 June 2007 Pages: 181 - 182
Mechanisms of aPL-mediated thrombosis: Effects of aPL on endothelium and platelets Mariano E. Vega-OstertagSilvia S. Pierangeli OriginalPaper 20 June 2007 Pages: 190 - 197
Antiphospholipid antibody effects on monocytes Alisa S. Wolberg OriginalPaper 20 June 2007 Pages: 198 - 204
Role of complement in antiphospholipid antibody-mediated thrombosis Kathleen M. O’Neil OriginalPaper 20 June 2007 Pages: 205 - 211
Antiphospholipid antibodies in response to infection Tadej AvčinNataša Toplak OriginalPaper 20 June 2007 Pages: 212 - 218
Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Erin A. S. ClarkRobert M. SilverD. Ware Branch OriginalPaper 20 June 2007 Pages: 219 - 225
Genetic factors in the pathogenesis of CPPD crystal deposition disease Ana Rita CoutoMatthew A. Brown OriginalPaper 20 June 2007 Pages: 231 - 236
Tumoral calcinosis: New insights for the rheumatologist into a familial crystal deposition disease Eli Sprecher OriginalPaper 20 June 2007 Pages: 237 - 242
Recent developments in crystal-induced inflammation pathogenesis and management Frédéric LiotéHang-Korng Ea OriginalPaper 20 June 2007 Pages: 243 - 250
Uric acid nephrolithiasis Scott E. LiebmanJeremy G. TaylorDavid A. Bushinsky OriginalPaper 20 June 2007 Pages: 251 - 257
Uricase and other novel agents for the management of patients with treatment-failure gout John S. SundyMichael S. Hershfield OriginalPaper 20 June 2007 Pages: 258 - 264